Barrow, Hanley, Mewhinney & Strauss
CNMD icon

Barrow, Hanley, Mewhinney & Strauss’s CONMED CNMD Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-157
Closed -$5.55K – 385
2026
Q1 		$5.55K Hold
157
– – ﹤0.01% 261
2025
Q4 		$6.37K Hold
157
– – ﹤0.01% 257
2025
Q3 		$7.38K Hold
157
– – ﹤0.01% 240
2025
Q2 		$8.18K Hold
157
– – ﹤0.01% 219
2025
Q1 		$9.48K Hold
157
– – ﹤0.01% 220
2024
Q4 		$10.7K Hold
157
– – ﹤0.01% 223
2024
Q3 		$11.3K Buy
+157
New +$11.1K ﹤0.01% 221

Other funds holding CNMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's CNMD Position: Q2 2026 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of CONMED (CNMD) in Q2 2026, closing a stake of 157 shares — an estimated $5.55K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in CNMD in Q3 2024 and held it in 7 quarters. The position peaked at $11.3K in Q3 2024. 246 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining CONMED position as of Q2 2026 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 157 CONMED shares in Q2 2026, an estimated $5.55K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in CONMED in Q3 2024 and held it in 7 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's CONMED position peaked at $11.3K in Q3 2024.
  • 246 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2026, filed 12 Aug 2026.